VivoSeq
Other

Adverse Effect

42

Pipeline Programs

3

Active Trials

20

Companies Involved

Adverse Effect is a moderately active landscape with 42 programs across 20 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Hikma Pharmaceuticals LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 13 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

84/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

95%

Small molecule

42 of 44 classified programs — the dominant modality here.

5%ALL OTHERSProtein / enzyme12%Vaccine12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.

Trial Status

32

clinical trials

Completed16 · 50%
Unknown status10 · 31%
Recruiting3 · 9%
Withdrawn2 · 6%
Terminated1 · 3%

Trial Activity

32 trials

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)